# Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Co

Source: https://onco.cc/trials/nct07537998/  
OnCo record `nct07537998` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial in colorectal cancer, run by Pei-Rong Ding, now recruiting.

## Summary

Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial. is a phase 2/3, randomised interventional study registered as NCT07537998 by Pei-Rong Ding, with a registry enrolment figure of 160 participants, started 2026-04-10 and due to reach its primary completion in 2027-04-10. Interventions recorded: intestinal fluid infusion; potable water. Conditions listed: Low Anterior Resection Syndrome; Rectal Cancer. Primary outcome: LARS score(m1). Colorectal eligibility wording from the registry: "* Patients with mid to low rectal cancer (within 10cm of the anal verge) who undergo radical DIXON+ileostomy surgery". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07537998
- Phase: 2/3
- Setting: Antegrade Intestinal Fluid Reinfusion Verse Water Infusion Through Prophylactic Ileal Stoma for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial.
- Sponsor: Pei-Rong Ding
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT07537998: https://clinicaltrials.gov/study/NCT07537998

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07537998.json